. https://doi.org/10.1172/JCI115600. cAMP regulation of the human thyrotropin-beta (TSH beta) gene cAMP was studied in two heterologous cell lines, a human embryonal kidney cell line (293) and a rat pituitary cell line (GH3). In 293 cells, human TSH beta gene expression was not stimulated by the adenylate cyclase activator forskolin or the cAMP analogue 8-bromo-cAMP (8-Br-cAMP). On the other hand, these agents induced human TSH beta gene expression 4-12-fold in GH3 cells. Deletion analysis demonstrated that the regions from +3 to +8 bp and from -128 to -61 bp were both necessary for cAMP stimulation. The latter region contains three DNA sequences homologous to a pituitary-specific transcription factor, Pit-1/GHF-1, DNA-binding site. Gelmobility assays demonstrated that a radiolabeled human TSH beta probe (-128 to -61 bp) formed five specific DNA-protein complexes with mouse thyrotropic tumor (MTT) nuclear extract and two specific complexes with in vitro translated Pit-1/GHF-1. Four of the five MTT complexes and both in vitro Pit-1/GHF-1 complexes were reduced or eliminated by excess of an unlabeled Pit-1/GHF-1 DNA-binding site from the rat growth hormone gene, but not a mutated version of the same DNA fragment, suggesting that Pit-1/GHF-1 or a closely related thyrotroph protein binds to these DNA sequences. In 293 cells, co-transfection of an expression vector containing the Pit-1/GHF-1 cDNA restored cAMP-responsiveness to the human TSH beta promoter (5. Deletion analysis demonstrated that the regions from +3 to +8 bp and from -128 to -61 bp were both necessary for cAMP stimulation. The latter region contains three DNA sequences homologous to a pituitary-specific transcription factor, Pit-1/ GHF-1, DNA-binding site. Gel-mobility assays demonstrated that a radiolabeled human TSHB6 probe (-128 to -61 bp) formed five specific DNA-protein complexes with mouse thyrotropic tumor (MTT) nuclear extract and two specific complexes with in vitro translated Pit-l/GHF-1. Four of the five MTT complexes and both in vitro Pit-l/GHF-1 complexes were reduced or eliminated by excess of an unlabeled Pit-1/ GHF-1 DNA-binding site from the rat growth hormone gene, but not a mutated version of the same DNA fragment, suggesting that Pit-l/GHF-1 or a closely related thyrotroph protein binds to these DNA sequences. In 293 cells, co-transfection of an expression vector containing the Pit-l/GHF-1 cDNA restored cAMP-responsiveness to the human TSH,6 promoter (5.2-and 6.6-fold maximal stimulation by 8-Br-cAMP and forskolin, respectively) but not the herpes virus thymidine kinase promoter (1.2-fold maximal stimulation by either agent).
Introduction
Thyrotropin (TSH),' like other pituitary glycoprotein hormones, contains two dissimilar noncovalently linked subunits, a and fl. Previous studies revealed a positive regulation of the synthesis and the secretion of TSH not only by its hypothalamic releasing hormone thyrotropin-releasing hormone (TRH) but also by agents acting through the cAMP system (1, 2) . A more recent study identified the neuropeptide arginine vasopressin as a possible candidate for a physiological stimulator of TSH secretion acting through the cAMP system (3) . In this study the efficiency of arginine vasopressin was comparable to that of TRH, which may act independently from the cAMP system (4) . Recent studies with pituitary cells in primary culture suggested that these regulators in some way also affect the production of both subunits at a pretranslational level (5, 6) . For the expression of the a-subunit gene, a stimulatory effect of both mediators has been clearly shown; whereas in the case of the (-subunit gene, the data are less clear.
TRH has clearly been shown to stimulate the transcriptional activity ofTSHj3 gene, but data on the importance ofthe cAMP system in regulating TSH(3 gene expression have been contradictory (5, 6) . A more recent study by Shupnik et al. (7) confirmed the initial observations of Franklyn et al. (6) that TSHB mRNA levels were increased in rat pituitary cells after treatment with forskolin, an activator of adenylate cyclase. In this study the effect of forskolin, TRH, and the protein kinase C activator 12-O-tetradecanoyl phorbol-13-acetate (TPA) was investigated (7) . Whereas TRH and TPA seemed to confer an induction of rat TSHB expression via regions between -520 and -204 bp, forskolin induction appeared to be primarily mediated by sequences downstream of -204 bp.
Many genes have been shown to be regulated in a positive way by cAMP or agents acting via the cAMP system. In these genes a consensus octamer sequence (CRE) (8-1 1) that func-tions as a cis-acting enhancer has been identified; and the transacting factor, cAMP response element-binding protein (CREB) that binds to this element has been isolated and characterized (12, 13) . However, not all the stimulatory effects of cAMP on gene expression can be attributed to this CRE.
Another DNA sequence reported to mediate induction by cAMP is the AP-2 binding site, which has been shown to confer stimulation by protein kinase A as well as protein kinase C (14) . In addition, recent data suggest that hormones and neurotransmitters that act through the cAMP system might induce the expression of certain pituitary hormone genes via cell-specific factors (15) (16) (17) . Stimulatory effects on expression of rat and human GH and rat PRL genes seemed to be mediated by sequences that differ from the classical CRE or the AP-2 sequences (15) (16) (17) . In most cases the responsive regions are located near the start site of transcription. In all reports cAMP or agents acting via cAMP resulted in an -10-fold induction of gene expression. In contrast to CRE-mediated stimulation, these DNA sequences conferred little or no cAMP induction to a heterologous promoter (15) .
In this study we investigated the role of the cAMP/protein kinase A system in the regulation ofhuman TSH,3 gene expression. Since no permanent TSH-producing cell line was available, the expression of chimeric human TSHf-chloramphenicol acetyltransferase (CAT) plasmids was studied in a embryonal human kidney cell line, 293, or a rat pituitary cell line, GH3. In GH3 but not 293 cells, cAMP analogues stimulated CAT activity -10-fold from plasmids containing the human TSH3 promoter; deletion analysis revealed that only 128 bp of 5'-flanking DNA and 8 bp of the first exon were sufficient for complete cAMP induction. Further studies identified the region from -128 bp to -61 bp and +3 to +8 bp as necessary for the cAMP effect. Since a promoter-specific induction was observed in a pituitary, but not a kidney, cell line, the involvement of a pituitary-specific trans-acting factor was postulated. In co-transfection experiments, an expression vector containing the pituitary-specific trans-acting factor (Pit-l/GHF-1) cDNA restored cAMP induction to the human TSH3 promoter in previously non-responsive cell line, 293. Therefore, we suggest that the cell-specific factor Pit-1/GHF- 1 Plasmid construction. The CAT gene was excised from pSVOCAT (18) using HindIII and BamHI. A -1200 to +7 fragment from the human TSHB gene was excised using BamHI and BstEII, and a -128/+7 fragment was obtained using EcoRI and BstEII. These fragments were ligated into the BamHI or EcoRI/BamHI site(s) of pUC 19 using a synthetic BstEII/HindIII adaptor (12 bp) or a synthetic BstEII/HindIII fragment containing the entire first exon. Since the adaptor reconstituted the BstEII site, these constructs contained +8 and not +7 bp of the 5' untranslated region.
Further deletion constructs were obtained using the polymerase chain reaction (PCR). 5' primers were synthesized with EcoRI or KpnI restriction sites and 3' primers with a HindIII sites. The -128/+8 construct was used as a template. The PCR products were ligated to the HindIII site of the CAT coding sequence and the product was inserted into the EcoRI/KpnI and BamHI sites of pUC 18/19 vectors. The construction of pTKCAT has been described previously (18) . The pTKCAT constructs containing regions of the human TSHB 5' flanking region were obtained by inserting PCR fragments containing KpnI and BamHI ends into their respective sites upstream of the herpes simplex thymidine kinase promoter in pTKCAT. p-128(AlI 18)/+2hTSHBCAT contains a 3-bp mutation of nucleotides -1 18 to -1 16 bp (TGA to GTC). p-28/ +8hTSH,3SVECAT contains the SV40 72-bp repeat enhancer element (gift of K. McKeon, National Institutes of Health, Bethesda, MD) inserted as a BamHI fragment into the parent plasmid, p-28/+8hTSH,3CAT. All DNA constructs were confirmed using both restriction enzyme analysis as well as DNA sequencing.
To correct for transfection efficiency, cell cultures were transfected with constructs containing the human GH coding sequence by use of either the herpes simplex thymidine kinase promoter (pTKGH) or the mouse metallo-thionein-I promoter (pXGH5). pTKGH was used in studies with treatment periods of 2 24 h. pXGH5 was used in the 8-h treatment experiments except where indicated.
Plasmids containing either the gene for a protein kinase A inhibitor protein (pRSVPKI) or a nonfunctional mutant (pRSVPKI mut) were a generous gift ofDr. R. Maurer (University of Iowa, Iowa City, IA). These plasmids are under the control of the Rous sarcoma virus promoter. The Pit-1/GHF-l plasmid is driven by the cytomegalovirus promoter (pCMVPit-1) and was obtained from Dr. L. Staudt (National Institutes of Health). In the respective control plasmid, the coding sequence for Pit-1/GHF-1 was excised with XbaI and BamHI and the ends were made blunt by SI nuclease and re-ligated (pCMV).
Cell culture, transfection, and CAT assays. 293 and GH3 cells were cultured in Dulbecco's modified essential medium supplemented with 10% fetal bovine serum and 4 mM L-glutamine. One day before transfection the cells were trypsinized and plated onto 100-mm dishes. Transfection was performed using the calcium phosphate precipitation method; the precipitate was applied for 16-18 h. Usually 25 ug of the human TSHBCAT constructs were transfected per dish, and 5 ,ug of a hGH construct was co-transfected to correct for transfection efficiency. The morning after transfection, cells were washed with serum-free medium and shocked for 2 min with 20% glycerol in Hepes saline (pH 7.5). Thereafter cells were incubated in serum-free Dulbecco's modified essential medium supplemented with 10 ,M ZnSO4, 100 ,uM MgSO4, 4 mM L-glutamine, 10 ,ug/ml insulin, 5 ,g/ml transferrin, 5 ng/ml selenite, and 1% bovine serum albumin (ITS medium). CAT activity in the cell lysate was determined after the indicated time of treat-ment as described (18) . The concentration of hGH was determined in the medium and the CAT activity was corrected for transfection efficiency.
Gel-mobility assay. A radiolabeled DNA fragment of the human TSH3 gene (-128 to -61 bp) and a -1 18 to -1 16-bp mutation of that same fragment (described above) was synthesized using the (21) . In addition, these cells have been used to study thyroid hormone inhibition of human TSHf gene expression. Transient expression experiments were performed with plasmids containing different lengths of the 5' flanking region coupled to the reporter gene, CAT (18) .
However, the effect ofcAMP on human TSHf3 gene expression in these cells revealed no significant stimulatory effect by the direct adenylate cyclase activator forskolin at 10 ,uM (1.4- fold induction, Fig. 1 ). This concentration has been shown to maximally activate the cAMP system in other expression systems. Since mRNA studies (6) suggested that there might be a cAMP effect on TSH( gene expression in primary pituitary cell cultures, transient transfection experiments were performed in GH3 cells, a rat pituitary cell line. This cell line has been used successfully for studies of the stimulatory effect of TRH on rat (22) and human TSHf gene expression (23). In GH3 cells transfected with a CAT construct containing -1200 to +8 bp of the human TSHB gene, forskolin induced CAT activity -12-fold ( Fig. 1) . A second construct containing only -128 to +8 bp retained full induction by forskolin. As shown below, 2.5-fold of this induction is due to a nonspecific effect of forskolin on the plasmids utilized in this study.
Since forskolin has been shown to have additional effects besides the activation ofadenylate cyclase (24) , it was necessary to confirm that elevated cellular cAMP levels mediated the stimulation of human TSHf gene expression in GH3 cells. Therefore, we tested its derivative, dideoxyforskolin, which does not activate adenylate cyclase but shares some ofthe nonspecific activities of forskolin, for its effect on the expression of chimeric human TSHBCAT constructs. Whereas forskolin treatment resulted in the expected 12-fold stimulation of CAT activity, dideoxyforskolin was without any stimulatory effect (data not shown).
Concentration-response and time course offorskolin induction. The concentration-response of stimulation by forskolin was tested with concentrations ranging from 0.32 to 25 ,M in cells transfected with p-128/+8hTSHOCAT construct. At the concentrations tested, the induction by this agent ranged from three to about eightfold. Half-maximal induction was observed at -0.5 ,M, and maximally effective induction was observed at concentrations of > 3.2 qM (data not shown). When cells were transfected with p-128/+8hTSHj3CAT and the expression of CAT activity studied over 8-72 h, the maximal activity (corrected for lysate protein) was observed after 24 h in untreated cells. On the other hand, forskolin-treated cells reached their maximal CAT activity after only 8 h. Since basal expression was still increasing up to the 24-h time point, the fold induction after 8 h of forskolin was larger than that observed at 24-72 h. At the early time points, forskolin induction was larger than 10-fold and dropped to 5-10-fold at the later time points (data not shown).
Further deletional analysis to localize cAMP-responsive regions. When the p-128/+8hTSHBCAT construct was compared with a construct that contained the complete first untranslated exon of the human TSHO gene (p-128/ +37hTSHf3CAT), the induction by either forskolin or the cAMP analogue 8-Br-cAMP was comparable. Forskolin stimulated CAT activity of both constructs 10-fold, whereas 8-BrcAMP (1 mM) resulted in a 5-6-fold induction (Table I ). This suggested that the bases from +9 to +37 ofthe first exon, which are necessary for the thyroid hormone inhibition of this gene, (Table I) lsfected with tivator con and incu-(pRSVPKI) or a nonfunctional mutant cDNA of the same nylate cyclase activator forskolin and the cAMP protein (pRSVPKImut) were cotransfected with p-128/ P for 8 h. Thereafter CAT activity was measured ection efficiency was monitored by co-transfecting +8hTSH#CAT (Table II) (25 late expression of either p-128/+8hTSHj3CAT or pTKCAT (Fig. 2) . These agents resulted in a maximal stimulation of onefold from pTKCAT and twofold from p-128/ +8hTSHj3CAT. Since both inductions were equal to or less than twofold, these data and the forskolin data presented earlier ( Fig. 1) (20) were performed with nuclear extract derived from MTT, a pure population of thyrotrophs; and as a control, nuclear extract derived from a nonpituitary cell line (HeLa cells) was also employed. MTT, but not HeLa, extract yielded five distinct DNA-protein complexes (Fig. 3 A, lane 2, M1-M5) . Each of these complexes proves to be specific since 100-fold molar excess of the unlabeled fragment (-128 to -61 bp) reduced or eliminated these complexes (Fig. 3 A, lane 5) .
As shown in Table III , three DNA sequences with high homology to the consensus Pit-l/GHF-1 binding site are found in this region. To test whether these complexes were due to binding of Pit-l/GHF-1, DNA fragments containing either a high-affinity Pit-l/GHF-1 DNA-binding site from the rat GH gene (rGH, -93 to -66 bp) or a mutated version of that same fragment (rGH-m) were employed. rGH-m contains a 5-bp mutation ofthe core Pit-1/GHF-1 DNA binding site present in rGH (rGH, 5' ATTTATTCAT 3'; rGH-m, 5' ATTTAGGTGG 3'). Fig. 3 A demonstrates that 100-fold molar excess of rGH (lane 8), but not rGH-m (lane 11), eliminated complexes M3-M5 and reduced the intensity ofthe M2 complex, whereas the Ml complex was eliminated only by -128 to -61 bp fragment.
In addition, 10-fold molar excess of rGH (lane 7) reduced in intensity complexes M3-M5. These data suggest that complexes M3-M5 and perhaps M2 are due to an interaction between Pit-l/GHF-l, or a closely related thyrotroph protein, and the radiolabeled -128 to -61-bp human TSHI# probe, whereas the Ml complex is due to an interaction with an unrelated thyrotroph protein and the radiolabeled probe. Fig. 3 Fig. 4 A demonstrates that in vitro synthesized Pit-l/GHFformed two specific complexes, P2 and P3, with the radiolabeled wild type -128 to -6 1-bp probe (Fig. 4 A, lane 3 ) that were not detected in an identical unprogrammed in vitro translation reaction (Fig. 4 A, lanes 2 and 13) . Complex P1 was detected in both unprogrammed and Pit-l/GHF-1-programmed in vitro translation reactions and thus represents a protein-DNA complex unrelated to Pit-l /GHF-l. The competitor DNA fragment rGH, but not rGH-m, eliminated both the P2 and P3 complexes (compare lanes 9 and 12). Since in vitro translation products are devoid of endogenous nuclear proteins, these data suggest that complexes P2 and P3 may represent binding of two or more and one Pit-I molecules to the -128 to -61 probe, respectively. Moreover, the relative mobility ofthe P2 and P3 complexes are similar, although not identical, to that ofthe M2 and M5 complexes generated by the MTT extract (Fig. 4 A, lanes 3 and 14, respectively) . Fig. 4 B demonstrates that a mutation of bases -1 8 to -1 16 bp in a -128 to -61 bp probe (MUT) eliminated the specific P2 and P3 complexes formed with in vitro translated Pit-l/GHF-l but not the P1 complex (compared lane 3, Fig. 4  A with lane 3, Fig. 4 B) . Moreover, the complexes formed be- 414 Steinfelder, Radovick, Mroczynski, Hauser, McClaskey, Weintraub, and Wondisford 5'-flanking region ofthe human TSHf3 gene contains a highaffinity Pit-1/GHF-J binding site. Since co-transfection of a Pit-1/GHF-1 expression vector into 293 cells restored cAMP induction to a contruct containing -128 to +8 bp of the human TSH(3 promoter, the ABCD assay was used to determine whether Pit-1/GHF-1 binds to this region with high affinity. Four biotinylated human TSHf DNA fragments (-122 to -101 bp, also referred to as hTSHf3-l; -107 to -86 bp; -76 to -55 bp; and -54 to -33 bp) were employed in the ABCD assay. The first three DNA fragments encompass one of the three DNA sequences with homology to the Pit-l/GHF-1 DNA-binding site (see Table III ). As negative controls, a thyroid hormone stimulatory element from the rat GH gene (-186 to -158 bp, rGH/T3) and a region from the long terminal repeat of AD 5 were used. Fig. 5 A demonstrates that hTSHf-122/-101 bound significantly more 35S-labeled Pit-l/ GHF-1 than the negative control fragments rGH/T3 and AD 5. hTSH3-107/-86 and hTSHf-76/-55, the two sites less homolgous to the Pit-1/GHF-DNA binding site, bound threefold less 35S-labeled Pit-l/GHF-than hTSH3-122/-101 but still significantly more than the negative control fragments. 35S-labeled Pit-l/GHF-binding to hTSHp-54/-33, which does not contain sequence homology to the Pit-I /GHF-1 DNA binding site, was not significantly different from its binding to the negative control fragments.
To determine the affinity of an interaction between 35S-labeled Pit-1/GHF-1 and hTSHf-122/-101 (hTSHf-1), the ABCD assay was again used. As a positive control, a biotinylated DNA fragment from the rat GH gene containing a highaffinity Pit-l/GHF-l binding site (-89 to -60 bp, rGH-l) was utilized; and as a negative control, AD 5 was employed. Fig. 5 B demonstrates that increasing amounts of both the hTSHf-and rGH-DNA fragments bound significantly more 35S-labeled Pit-I/GHF-than the negative control fragment, AD 5. The affinity of the hTSH,3-1 and rGH-DNAbinding sites for Pit-l/GHF-was calculated from this data using Scatchard analysis. The Kd of the rGH-site for Pit-l/ GHF-1 (2.9 nM) is similar to that reported by Ingraham et al. (0.8 nM, reference 26). The hTSHB-fragment exhibited a 2.6-fold lower affinity for Pit-l/GHF-with a Kd of 7.5 nM.
Discussion
The use of the pituitary cell line GH3 allowed us to study the involvement ofthe cAMP or protein kinase A in the regulation of the expression of the human TSHf gene. In this system a 10-fold induction by forskolin and a 5-6-fold induction by 8-Br-cAMP was conserved in a plasmid containing only 128 bp of the promoter region and 8 bp of the first untranslated exon of the gene. No promoter-specific induction by forskolin was observed in the non-pituitary cell line 293. These data are in good agreement with observations of cell-specific and cAMPregulated expression of the rat PRL and rat and human GH genes in this or related cell lines (15) (16) (17) . In all these studies an regions from -128 to -61 and +3 to +8 bp were both important for this cAMP induction (Table I and Fig. 6) . The 1.8-2.5-fold effect of cAMP on the expression of the control plasmids, pTKCAT and pUCCAT, is similar to the effect ofcAMP on CAT expression from other promoters, such as the Rous sarcoma virus (11, 27) , mouse mammary tumor virus (15) , and herpes simplex thymidine kinase (27) Gel-mobility assays of a radiolabeled human TSHB probe from -128 to -61 bp indicate that Pit-l/GHF-1, or a closely related thyrotroph protein, interacts with this region. Moreover, a DNA fragment from this region, containing -122 to -101 bp of the human TSHf3 gene, bound 35S-labeled Pit-l/ GHF-1 with high affinity, although the affinity of this interaction was lower than that observed with the high-affinity binding site in the rat GH gene (Kd = 7.5 vs. 2.9 nM, respectively). The apparent differences in mobilities between protein-DNA complexes generated by MTT nuclear extract and in vitro translated Pit-1/GHF-1 may represent differences between authentic Pit-I /GHF-1 in the thyrotroph and in vitro synthesized Pit-l/GHF-l. Moreover, post-translational modifications of Pit-l/GHF-1 in the thyrotroph could also explain the differences in mobilities. Alternatively, the protein-DNA complexes generated by MTT extract may contain a nuclear protein closely related but not identical to Pit-l/GHF-1. Recently, Alexander et al. (32) have described a lactotroph-specific transcription factor that binds to corresponding regions in the murine TSH3 gene. This larger molecular weight protein is related to Pit-l/GHF-1 and migrates as a triplet between 36 and 40 kD. Thus, the apparent decrease in mobility between protein-DNA complexes generated by MTT nuclear extract and in vitro translated Pit-1/GHF-1 could also be explained by an interaction between the radiolabeled probe and lactotroph-specific transcription factor or another putative thyrotroph-specific factor.
Co-transfection studies using an expression vector containing the Pit-l/GHF-1 cDNA also support the hypothesis that this or a related transcription factor is necessary for cAMP stimulation of the human TSHB gene. In a previously unresponsive cell line, 293, co-transfection of pCMVPit-1 restored cAMP stimulation to the human TSHB gene. Since expression of Pit-l/GHF-l is under control ofa viral promoter, these data suggest that cAMP may directly activate Pit-1/GHF-I via phosphorylation, resulting in an increase in human TSHJ gene expression. Recently, in fact, Kapiloff et al. (33) have shown that Pit-l/GHF-1 is phosphorylated by cAMP analogues in vitro and in vivo at two sites and that phosphorylation at one site alters binding of Pit-l/GHF-1 to various DNA elements.
Importantly, though, it has also been recently shown that the expression of the Pit-I /GHF-1 gene is induced approximately threefold by cAMP (34) , and two CREB binding sites were Thyrotropin-fl Gene Regulation by Cyclic Adenosine Monophosphate 417 -~~-found in the 5' flanking region ofthe Pit-l/GHF-l gene. Therefore, cAMP might also raise intracellular levels ofPit-I /GHF-1 via phosphorylation of CREB and activation of the Pit-l/ GHF-l gene, as has been shown for other cAMP-regulated genes (35). This induction of Pit-l/GHF-l could then stimulate the expression of the human TSHf3 gene via an indirect mechanism.
In the case of the common glycoprotein a-subunit gene, cAMP activates transcription via interaction of CREB with a CRE in the 5' flanking region (8, 9) . The mechanism of this induction is considered to be direct via preexisting proteins since inhibition of protein synthesis did not affect cAMP induction. On the other hand, data on the regulation of the expression of the hCG j3 subunit are less clear. Like the human TSHf3 gene, this gene does not contain a classical CRE. Differences in the kinetics of cAMP stimulation of a and CG,3 transcription rates (36) and activation of transiently expressed fusion genes (37) (38) . In contrast, in JEG-3 cells the stimulation of both a and CG3 gene transcription seemed to be mediated by stable proteins (39); therefore, cAMP was thought to directly stimulate induction ofboth subunit genes. Future studies of cAMP stimulation of human TSH3 gene expression will explore whether this stimulation is via a direct mechanism, indirect mechanism, or a combination of both mechanisms.
In conclusion, the expression of chimeric human TSHBCAT plasmids in the pituitary GH3 cells is positively regulated by the cAMP and is the result ofactivation ofthe catalytic subunit of the protein kinase A. Regions mediating the major portion ofthis induction were localized between -128 and -91 bp and +3 to +8 bp. The involvement of Pit-l/GHF-l, or a closely related protein in the thyrotroph, in the stimulation of human TSHB gene expression by cAMP is suggested.
